Who this treatment now reaches — and why the list has grown

Many patients arrive at a cartilage consultation having already been told that biological repair is not for them — their OA is too widespread, their defect too large, or they are simply 'too old' for regenerative treatment. For a significant proportion of those patients, the injectable form of ChondroFiller® changes that picture.

The original indication for ChondroFiller® was arthroscopic placement of a collagen scaffold into a contained focal chondral defect. The injectable pathway — an ultrasound-guided outpatient procedure — has since extended clinical scope considerably. Three groups now commonly qualify who would previously have been directed straight towards joint replacement: patients with diffuse cartilage wear across the joint rather than a single discrete lesion, patients for whom marrow-stimulation techniques or ACI/MACI are unsuitable, and older active patients seeking a joint-preservation option before committing to a total knee replacement.

The common thread across all three groups is that candidacy turns on imaging rather than on demographic proxies. Age, BMI, and symptom duration are not the primary filters — MRI review of the actual cartilage picture is. Each of these sub-groups is examined in the sections below.

What ChondroFiller actually does inside the knee

ChondroFiller® occupies a distinct category from the injections most knee patients have already encountered. Unlike a corticosteroid, it does not suppress inflammation; unlike hyaluronic acid, it does not lubricate the joint or add cushioning fluid. It is a CE-marked Class III medical device — a sterile, injectable Type I/III collagen scaffold that works by giving the body's own cells a physical template to build on.

Placed under ultrasound guidance at an outpatient appointment, the collagen solution gels within minutes of entering the joint, forming a stable three-dimensional matrix directly against the damaged cartilage surface. No theatre admission, no incision.

The repair process that follows is called acellular matrix-induced chondrogenesis — in plain terms, the scaffold carries no cells of its own, but draws the patient's progenitor cells from surrounding synovial tissue and subchondral bone. Those cells migrate into the collagen matrix, mature into chondrocytes, and gradually deposit new cartilage tissue as the scaffold is naturally resorbed. The repair tissue that forms is hyaline-like in character, which is considered structurally superior to the fibrocartilage produced by older marrow-stimulation techniques such as microfracture.

This is not an injection designed to provide immediate relief. The regeneration timeline runs to six to twelve months, and the structural improvement — objectively measurable on follow-up MRI — reflects genuine tissue rebuilding rather than symptom suppression.

Defect size and OA grade — where the usual ceilings do not apply

Traditional cartilage repair techniques each operate within a size envelope. Microfracture is generally restricted to lesions under 2–4 cm²; MACI and ACI require a well-defined, contained defect to implant and stabilise the graft; mosaicplasty similarly demands a discrete plug site. Patients whose cartilage damage exceeds those boundaries — or whose wear is diffuse rather than focal — have historically had nowhere to go between physiotherapy and joint replacement.

The injectable route works on a different principle. Because ChondroFiller® is delivered as a self-gelling fluid under ultrasound guidance, it can coat the entire articular surface of the knee in a single outpatient appointment rather than filling one defined cavity. There is no ceiling on defect area — the relevant question is whether residual cartilage tissue is present to give the scaffold a surface to adhere to and support. A patient described as 'too widespread for microfracture' or 'defect too large for MACI' may therefore still be a candidate, provided the joint has not reached end-stage disease where no viable cartilage substrate remains at all.

Diffuse cartilage wear broadly corresponding to Kellgren-Lawrence Grades II and III is within scope on that basis. Grade III and IV disease has been treated via intra-articular injection, where the gelled scaffold functions as a top-down mechanical cushion across worn surfaces rather than a localised defect plug.

Where disease spans more than one compartment, or where the surface area is large, dosing scales accordingly: two or three product units cover the full extent, making the approach genuinely adaptable to multi-compartment OA rather than single-lesion repair.

Age, post-traumatic damage, and the pre-replacement patient

Three patient groups frequently assume they fall outside the reach of cartilage repair. Each deserves a direct answer.

Older active patients considering knee replacement

The injectable collagen scaffold pathway carries no upper age limit. This matters because the biological rationale differs from marrow-stimulation techniques: ChondroFiller® does not rely on the marrow's progenitor-cell output, which declines with age. Instead, the scaffold recruits progenitor cells from surrounding synovial tissue — a reservoir that remains available well into later decades. The product is explicitly positioned as a joint-preservation option for active patients in their 60s, 70s and beyond who have been advised to proceed to total knee replacement but wish to attempt a preservation step first. This directly addresses the clinical gap left when biological repair techniques — typically restricted to younger patients — are ruled out, yet replacement feels premature.

Post-traumatic cartilage damage and osteochondritis dissecans

Post-traumatic chondral lesions, osteochondritis dissecans, and cartilage damage arising after meniscal surgery or ligament reconstruction (including ACL reconstruction) are recognised qualifying indications, provided the wider joint environment is structurally sound. This group is frequently left without good options: standard biological repair techniques often require an intact surrounding cartilage rim and predictable defect geometry that post-traumatic damage does not always provide.

Patients who have already tried other interventions

Patients who have had a prior cartilage procedure that failed to provide lasting relief — or who cannot undergo marrow stimulation because subchondral bone involvement disrupts the drill-access route — represent a distinct sub-group for assessment. Should the injection approach ultimately not achieve durable relief, available evidence suggests that prior ChondroFiller® treatment does not materially complicate a subsequent knee replacement; however, this finding comes from early-stage data rather than large controlled studies, and individual candidacy should be confirmed at consultation.

Structural prerequisites that genuinely do matter

Not every knee with cartilage wear is ready for the injectable scaffold pathway. Three mechanical factors are genuine gating criteria — not soft recommendations.

Ligament stability. Untreated instability across the ACL, PCL, or collateral ligaments creates abnormal shear forces at the articular surface. A scaffold placed into an unstable joint will be subjected to loading patterns it cannot withstand. Ligament reconstruction or appropriate bracing must therefore be addressed before, or concurrent with, the injection to avoid overloading the repair environment.

Coronal-plane alignment. Significant varus or valgus malalignment concentrates ground-reaction force onto whichever compartment is already under stress, rapidly degrading any repair that forms there. Where malalignment is the primary driver of wear rather than its consequence, corrective planning — typically high tibial osteotomy (HTO) or distal femoral osteotomy (DFO) — is considered before cartilage intervention.

Meniscal deficit. A missing or substantially deficient meniscus alters tibiofemoral load distribution. This is not an automatic exclusion, but an active meniscal deficit that is driving the cartilage wear must be accounted for — whether through concurrent meniscal surgery or careful load management — rather than treating the cartilage surface in isolation.

What 'bone on bone' on X-ray actually means for candidacy

Plain radiographs detect joint-space narrowing but cannot resolve the remaining thickness, structural integrity, or matrix hydration of residual cartilage. A patient told they are 'bone on bone' on an X-ray may retain salvageable cartilage tissue that MRI characterises in detail. Cartilage-layer assessment — including T2 mapping, which reflects matrix organisation — is the tool that determines whether viable scaffold substrate exists. Symptom duration, BMI, and radiograph grade alone cannot answer that question; MRI review does.

Outcomes and evidence — what the data show and where gaps remain

Three tiers of evidence underpin ChondroFiller® use, and conflating them does patients a disservice.

The strongest data covers focal chondral defects. Across more than 19,000 cases globally, the complaint rate sits at approximately 0.06% — a safety profile that is difficult to dispute. Within published focal-defect cohorts, IKDC scores improve by roughly 30 points at 12 months, and MOCART MRI regeneration scores of 70 to 87 reflect measurable structural change at the repair site. These are the figures with the most methodological weight behind them.

The second tier covers the broader diffuse-OA and pre-replacement indication. Mechanistically, the rationale is sound: a scaffold that coats the articular surface can function as a shock-absorbing matrix regardless of whether wear is focal or diffuse. Clinical experience across a large case volume supports the approach. What is absent is a dedicated randomised controlled trial in Kellgren-Lawrence Grade III/IV patients treated by injection. The broader indication is clinically credible but not yet RCT-confirmed.

The third gap concerns long-term durability. How benefit is sustained in high-grade OA beyond one to two years is not yet established in controlled trials. Whether initial functional gains persist, plateau, or attenuate in that population remains an open research question.

For any individual patient, these distinctions matter most at the point of candidacy review. Imaging-led assessment — MRI characterising residual cartilage thickness, matrix quality, and joint mechanics — is what translates population-level data into an individual-level decision.